3. U.S. Food and Drug Administration. Isoniazid (INH) [prescribing information]. Silver Spring, MD: FDA; 2016.
4. Lempens, P., Meehan, C.J., Vandelannoote, K. et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep 8, 3246 (2018). doi:10.1038/s41598-018-21378-x
6. DrugBank Online. Isoniazid (DB00951). Updated 2024.
10. Kemenkes RI. Petunjuk Teknis Manajemen dan tatalaksana TB Anak. Ministry of Health of the Republic of Indonesia. 2016. p. 3.
11. Drugs.com. Isoniazid Monograph. Drugs.com. Updated 2024.
12. Klein DJ, Boukouvala S, McDonagh EM, et al. PharmGKB Summary: Isoniazid Pathway, Pharmacokinetics (PK). Pharmacogenet Genomics. 2016;26(9):436–44.
13. Gumbo T. Chemotherapy of Tuberculosis, Mycobacterium avium Complex Disease, and Leprosy. In: Brunton L, Dandan R, Knollmann B, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition. 13th ed. Mc Graw Hill; 2018. p. 1072–4.